Blueprint Medicines (BPMC) Price & Analysis

Compare

609 Followers

BPMC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$73.04 - $129.65

Previous CloseN/A

Volume168.58K

Average Volume (3M)3.85M

Market Cap

$8.37B

Enterprise Value$6.03B

Total Cash (Recent Filing)$576.24M

Total Debt (Recent Filing)$122.75M

Price to Earnings (P/E)―

Beta1.31

Next Earnings

Jul 30, 2025

EPS Estimate

-0.47

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding49,202,000

10 Day Avg. Volume5,310,264

30 Day Avg. Volume3,852,750

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.72

Enterprise Value/Revenue10.72

Enterprise Value/Gross Profit11.18

Enterprise Value/Ebitda-45.98

Forecast

1Y Price Target

$130.71

Price Target Upside0.97% Upside

Rating ConsensusHold

Number of Analyst Covering18

Bulls Say, Bears Say

Bulls Say

Acquisition StrategySanofi's announced acquisition of BPMC for $129/share plus CVRs complements Sanofi's existing footprint/portfolio in rare disease and immunology.

Financial PerformanceSanofi expects the acquisition to be immediately accretive to gross margin and accretive to operating income and EPS after 2026.

Bears Say

Competitive RiskThe timing of the announcement is curious given the expected pivotal data from Cogent’s SUMMIT trial, which could have material implications for the value of Blueprint’s systemic mastocytosis franchise.

Market ConcernsMacro issues affecting biotech, such as pricing and tariffs, remain a concern for investors.

Blueprint Medicines News

Cogent Biosciences price target raised to $22 from $15 at Citi

Citi raised the firm’s price target on Cogent Biosciences (COGT) to $22 from $15 and keeps a Buy...

29d ago

BPMC

COGT

Blueprint Medicines Completes $9.1B Merger, Delists from Nasdaq

An update from Blueprint Medicines ( ($BPMC) ) is now available. On July 17, 2025, Blueprint Medicines completed...

29d ago

BPMC

Blueprint Medicines Holds Annual Stockholders Meeting

Blueprint Medicines ( ($BPMC) ) has provided an announcement. On June 18, 2025, Blueprint Medicines held its Annual...

2M ago

BPMC

Blueprint Medicines downgraded to Equal Weight from Overweight at Wells Fargo

Wells Fargo downgraded Blueprint Medicines (BPMC) to Equal Weight from Overweight with a price target of $129, down...

2M ago

BPMC

Blueprint Medicines announces data reinforcing sustained efficacy of AYVAKIT

Blueprint Medicines (BPMC) “announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates...

2M ago

BPMC

Blueprint Medicines price target raised to $129 from $88 at UBS

UBS analyst David Lai raised the firm’s price target on Blueprint Medicines (BPMC) to $129 from $88 and...

2M ago

BPMC

Blueprint Medicines price target raised to $129 from $102 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Blueprint Medicines (BPMC) to $129 from $102 and keeps an...

2M ago

SNY

BPMC

Hold Rating on Blueprint Medicines Amid Sanofi Acquisition and Market Uncertainties

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Blueprint Medicines (BPMC...

2M ago

BPMC

Apple downgraded, Snowflake upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

Blueprint Medicines upgraded to Neutral from Sell at Citi

Citi upgraded Blueprint Medicines (BPMC) to Neutral from Sell with a price target of $129, up from $83,...

2M ago

BPMC

Blueprint Medicines downgraded to Neutral from Buy at Guggenheim

Guggenheim analyst Michael Schmidt downgraded Blueprint Medicines (BPMC) to Neutral from Buy with a $132 price target after...

2M ago

BPMC

Reddit initiated, Pinterest upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

AAP

CAH

Blueprint Medicines downgraded to Equal Weight from Overweight at Stephens

Stephens downgraded Blueprint Medicines (BPMC) to Equal Weight from Overweight with a price target of $135, down from...

2M ago

BPMC

Sanofi’s Strategic Acquisition of Blueprint Medicines: A Buy Recommendation by Derek Archila

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Blueprint Medicines (BPMC...

2M ago

BPMC

BPMC FAQ

What was Blueprint Medicines Corp.’s price range in the past 12 months?

Blueprint Medicines Corp. lowest stock price was $73.04 and its highest was $129.65 in the past 12 months.

What is Blueprint Medicines Corp.’s market cap?

Blueprint Medicines Corp.’s market cap is $8.37B.

When is Blueprint Medicines Corp.’s upcoming earnings report date?

Blueprint Medicines Corp.’s upcoming earnings report date is Jul 30, 2025 which is 17 days ago.

How were Blueprint Medicines Corp.’s earnings last quarter?

Currently, no data Available

Is Blueprint Medicines Corp. overvalued?

According to Wall Street analysts Blueprint Medicines Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Blueprint Medicines Corp. pay dividends?

Blueprint Medicines Corp. does not currently pay dividends.

What is Blueprint Medicines Corp.’s EPS estimate?

Blueprint Medicines Corp.’s EPS estimate is -0.47.

How many shares outstanding does Blueprint Medicines Corp. have?

Blueprint Medicines Corp. has 49,202,000 shares outstanding.

What happened to Blueprint Medicines Corp.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Blueprint Medicines Corp.?

Currently, no hedge funds are holding shares in BPMC

Blueprint Medicines Stock Smart Score

Outperform

Fundamentals

Return on Equity

-47.71%

Trailing 12-Months

Asset Growth

15.13%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Blueprint Medicines Corp.

Blueprint Medicines Corporation (BPMC) is a precision therapy company focused on developing targeted treatments for genomically defined cancers, rare diseases, and cancer immunotherapy. The company leverages its proprietary scientific platform to create small molecule medicines that selectively target genetic drivers of disease. Blueprint Medicines aims to improve patient outcomes through the development of transformative therapies that address the underlying causes of various diseases.

Blueprint Medicines (BPMC) Earnings & Revenues

Historic Earnings Reports

BPMC Company Deck

BPMC Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Despite some challenges in the first quarter and international markets, Blueprint Medicines shows strong performance with significant revenue growth, successful pipeline advancements, and a solid financial position. The sentiment is largely positive, driven by the strong market reception of AYVAKIT and increased revenue guidance.View all BPMC earnings summaries

BPMC Stock 12 Month Forecast

Average Price Target

$130.71

▲(0.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"84":"$84","97":"$97","110":"$110","123":"$123","136":"$136"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$135.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$130.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":129,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$129.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[84,97,110,123,136],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,128.34,128.8523076923077,129.36461538461538,129.87692307692308,130.38923076923078,130.90153846153845,131.41384615384615,131.92615384615385,132.43846153846155,132.95076923076923,133.46307692307693,133.97538461538463,134.4876923076923,{"y":135,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,128.34,128.5223076923077,128.70461538461538,128.88692307692307,129.06923076923078,129.25153846153847,129.43384615384616,129.61615384615385,129.79846153846154,129.98076923076923,130.16307692307694,130.34538461538463,130.52769230769232,{"y":130.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,128.34,128.39076923076922,128.44153846153847,128.4923076923077,128.54307692307694,128.59384615384616,128.64461538461538,128.69538461538463,128.74615384615385,128.79692307692306,128.8476923076923,128.89846153846153,128.94923076923078,{"y":129,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":109.18,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.54,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.62,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.53,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.94,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >